miR-596 as a novel prognostic biomarker and tumor suppressor in breast cancer through targeting EIF5AL1.
[BACKGROUND] In terms of global incidence and mortality, breast cancer continues to surpass all other cancers affecting women.
- p-value P < 0.001
- p-value P < 0.05
APA
Huang R, Jiang Y, et al. (2026). miR-596 as a novel prognostic biomarker and tumor suppressor in breast cancer through targeting EIF5AL1.. Hereditas, 163(1), 28. https://doi.org/10.1186/s41065-026-00641-6
MLA
Huang R, et al.. "miR-596 as a novel prognostic biomarker and tumor suppressor in breast cancer through targeting EIF5AL1.." Hereditas, vol. 163, no. 1, 2026, pp. 28.
PMID
41566561
Abstract
[BACKGROUND] In terms of global incidence and mortality, breast cancer continues to surpass all other cancers affecting women.
[METHODS] To explore the role of miR-596, qRT-PCR was applied to measure its expression in tissue and cell samples from 137 enrolled subjects. The regulatory interaction between miR-596 and EIF5AL1 was verified by dual-luciferase reporter assays. CCK-8 and Transwell assays were utilized to respectively measure the proliferation, migration, and invasion capabilities of the two breast cancer cell lines, MCF-7 and MDA-MB-231.
[RESULTS] A significant downregulation of miR-596 was observed in breast cancer tissues and cell lines (all P < 0.001). Clinically, reduced miR-596 expression was associated with advanced TNM stage, lymph node metastasis, and inferior overall survival (P < 0.05). EIF5AL1 was validated as a direct target gene of miR-596, and their expression levels were inversely correlated in clinical samples (r = -0.801, P < 0.001). Reintroduction of miR-596 markedly suppressed the proliferation, migration, and invasion of cancer cells, effects that were largely reversed by overexpressing EIF5AL1 (all P < 0.001).
[CONCLUSION] In breast cancer, miR-596 suppresses malignancy and predicts prognosis by targeting EIF5AL1. Thus, therapeutic modulation of this axis offers novel avenues for treatment and risk assessment.
[METHODS] To explore the role of miR-596, qRT-PCR was applied to measure its expression in tissue and cell samples from 137 enrolled subjects. The regulatory interaction between miR-596 and EIF5AL1 was verified by dual-luciferase reporter assays. CCK-8 and Transwell assays were utilized to respectively measure the proliferation, migration, and invasion capabilities of the two breast cancer cell lines, MCF-7 and MDA-MB-231.
[RESULTS] A significant downregulation of miR-596 was observed in breast cancer tissues and cell lines (all P < 0.001). Clinically, reduced miR-596 expression was associated with advanced TNM stage, lymph node metastasis, and inferior overall survival (P < 0.05). EIF5AL1 was validated as a direct target gene of miR-596, and their expression levels were inversely correlated in clinical samples (r = -0.801, P < 0.001). Reintroduction of miR-596 markedly suppressed the proliferation, migration, and invasion of cancer cells, effects that were largely reversed by overexpressing EIF5AL1 (all P < 0.001).
[CONCLUSION] In breast cancer, miR-596 suppresses malignancy and predicts prognosis by targeting EIF5AL1. Thus, therapeutic modulation of this axis offers novel avenues for treatment and risk assessment.
MeSH Terms
Humans; MicroRNAs; Breast Neoplasms; Female; Peptide Initiation Factors; Prognosis; Biomarkers, Tumor; Middle Aged; Cell Proliferation; RNA-Binding Proteins; Cell Movement; Cell Line, Tumor; Eukaryotic Translation Initiation Factor 5A; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Adult; MCF-7 Cells
같은 제1저자의 인용 많은 논문 (5)
- Combining AI to reveal CCDC3-mediated pathways of colorectal cancer liver metastasis.
- Kaixuan Qibi granules attenuate myocardial fibrosis through BRD4 blockade regulated by the NF-κB/NLRP3 signaling pathway.
- Pretreatment emotional distress and peripheral biomarkers predict immune checkpoint inhibitor response in people with advanced inoperable gastroesophageal cancer.
- Correspondence to editorial 2 on "Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues".
- Correspondence to editorial 1 on "Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues".